A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell
lung cancer (SCLC) patients without disease progression after first-line platinum containing
chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression
after first-line platinum containing chemotherapy, and orr in SCLC patients with recurrence
or progression after second-line and above treatment,Evaluation of the effectiveness of
al8326 monotherapy in small cell lung cancer.